Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA

doi:10.1016/j.jalz.2016.02.002

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA

Radiology

Research output: Contribution to journal › Review article

497 Scopus citations

Abstract

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

Original language	English (US)
Pages (from-to)	292-323
Number of pages	32
Journal	Alzheimer's and Dementia
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2016.02.002
State	Published - Mar 1 2016

Keywords

Alzheimer's disease
Amyloid PET
Asymptomatic
Biomarkers
Blood biomarkers
CSF biomarkers
Diagnostic criteria
Genetics
MRI
Pathophysiology
Preclinical
Tau PET

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2016.02.002

Fingerprint Dive into the research topics of 'Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria'. Together they form a unique fingerprint.

Cite this

Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA (2016). Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 12(3), 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

Preclinical Alzheimer's disease : Definition, natural history, and diagnostic criteria. / Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA.

In: Alzheimer's and Dementia, Vol. 12, No. 3, 01.03.2016, p. 292-323.

Research output: Contribution to journal › Review article

@article{2839f13a596143f6a25b9878583b2ccb,

title = "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria",

abstract = "During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this {"}silent{"} stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.",

keywords = "Alzheimer's disease, Amyloid PET, Asymptomatic, Biomarkers, Blood biomarkers, CSF biomarkers, Diagnostic criteria, Genetics, MRI, Pathophysiology, Preclinical, Tau PET",

author = "{Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on {"}The Preclinical State of AD{"}; July 23, 2015; Washington DC, USA} and Bruno Dubois and Harald Hampel and Feldman, {Howard H.} and Philip Scheltens and Paul Aisen and Sandrine Andrieu and Hovagim Bakardjian and Habib Benali and Lars Bertram and Kaj Blennow and Karl Broich and Enrica Cavedo and Sebastian Crutch and Dartigues, {Jean Fran{\c c}ois} and Charles Duyckaerts and St{\'e}phane Epelbaum and Frisoni, {Giovanni B.} and Serge Gauthier and Remy Genthon and Gouw, {Alida A.} and Habert, {Marie Odile} and Holtzman, {David M.} and Miia Kivipelto and Simone Lista and Molinuevo, {Jos{\'e} Luis} and O'Bryant, {Sid E.} and Rabinovici, {Gil D.} and Christopher Rowe and Stephen Salloway and Schneider, {Lon S.} and Reisa Sperling and Marc Teichmann and Carrillo, {Maria C.} and Jeffrey Cummings and Jack, {Cliff R.}",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.jalz.2016.02.002",

language = "English (US)",

volume = "12",

pages = "292--323",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Preclinical Alzheimer's disease

T2 - Definition, natural history, and diagnostic criteria

AU - Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA

AU - Dubois, Bruno

AU - Hampel, Harald

AU - Feldman, Howard H.

AU - Scheltens, Philip

AU - Aisen, Paul

AU - Andrieu, Sandrine

AU - Bakardjian, Hovagim

AU - Benali, Habib

AU - Bertram, Lars

AU - Blennow, Kaj

AU - Broich, Karl

AU - Cavedo, Enrica

AU - Crutch, Sebastian

AU - Dartigues, Jean François

AU - Duyckaerts, Charles

AU - Epelbaum, Stéphane

AU - Frisoni, Giovanni B.

AU - Gauthier, Serge

AU - Genthon, Remy

AU - Gouw, Alida A.

AU - Habert, Marie Odile

AU - Holtzman, David M.

AU - Kivipelto, Miia

AU - Lista, Simone

AU - Molinuevo, José Luis

AU - O'Bryant, Sid E.

AU - Rabinovici, Gil D.

AU - Rowe, Christopher

AU - Salloway, Stephen

AU - Schneider, Lon S.

AU - Sperling, Reisa

AU - Teichmann, Marc

AU - Carrillo, Maria C.

AU - Cummings, Jeffrey

AU - Jack, Cliff R.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

AB - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

KW - Alzheimer's disease

KW - Amyloid PET

KW - Asymptomatic

KW - Biomarkers

KW - Blood biomarkers

KW - CSF biomarkers

KW - Diagnostic criteria

KW - Genetics

KW - MRI

KW - Pathophysiology

KW - Preclinical

KW - Tau PET

UR - http://www.scopus.com/inward/record.url?scp=84962325429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962325429&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.02.002

DO - 10.1016/j.jalz.2016.02.002

M3 - Review article

C2 - 27012484

AN - SCOPUS:84962325429

VL - 12

SP - 292

EP - 323

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -